Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA:0K91) is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. They are currently working on Lucid-MS, a compound that has shown promise in treating multiple sclerosis. They also developed unbuzzd™ and spun out an OTC version to Celly Nutrition Corp., in which Quantum BioPharma retains a 25.71% ownership stake.
Upgrade your investments
The global hangover cure products market size was valued at USD 2.05 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 14.8% from 2023 to 2030 when it is expected to reach a value of USD C.2 billion.
Until now, there is no effective product that reverses the effects of alcohol efficiently.
Restores mental alertness and improves cognition post-alcohol consumption in an
average of 15-30 minutes.
Proprietary formulation of extracts, vitamins, and minerals helps with liver and brain function.
Ingredients help reduce BAC faster than what the body would do naturally.
You invested in a night out
You invested in drinking
You invested so much, you have a hangover
Invest in Unbuzzd - Quantum BioPharma Ltd. (NASDAQ: QNTM)
Where innovation meets returns, invest in QNTM
Quantum Biopharma is known for its innovative approach in the biopharmaceutical sector, focusing on developing therapies that harness biological processes. Here are some potential business highlights for a company like Quantum Biopharma:
Innovative Therapies: Developing cutting-edge biopharmaceuticals targeting unmet medical needs, particularly in areas like oncology, autoimmune diseases, or infectious diseases.
Strategic Partnerships: Collaborations with research institutions and pharmaceutical companies to enhance R&D capabilities and expedite the development process.
Intellectual Property: Strong portfolio of patents that protects proprietary technologies and therapies, ensuring a competitive edge in the market.
Funding and Investment: Securing significant funding from venture capital, grants, or partnerships that support ongoing research and development initiatives.
Regulatory Milestones: Achieving key regulatory approvals that pave the way for market entry of new products.
Market Expansion: Plans for global market entry or expansion into new therapeutic areas, broadening the potential customer base.
Expertise and Leadership: A strong leadership team with deep expertise in biopharma, guiding the company through its growth phases.
These highlights would position Quantum Biopharma LTD as a forward-thinking player in the biopharmaceutical landscape. For the most accurate and detailed information, please refer to the company’s latest reports or press releases.
Invest with QNTM, where opportunity meets growth
Invest today – Enjoy tomorrow Call your Broker Now
DISCLAIMER
Snapmediagroup.net and Vanderbiltreport.com are owned and operated by SMG a US-based corporation. We have received compensation of up to $100,000 from KTM regarding the profiling of Quantum BioPharma Ltd (Nasdaq: QNTM) starting on October 1, 2024. It is important to note that we do not own any shares in QNTM: NASDAQ.
コメント